ArticleMolecular oncology2016
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
Article in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.Cancer immunology, immunotherapy : CII · 2019Trial
- Deep learning model and omics screening highlight angiotensinogen as a 5-methylcytosine (mFrontiers in immunology · 2026Article
- Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study.Journal of neuro-oncology · 2025Article
- Article
- Evaluating glioblastoma tumour sphere growth and migration in interaction with astrocytes using 3D collagen-hyaluronic acid hydrogels.Journal of materials chemistry. B · 2023Article
- Bioinformatics Strategies to Identify Shared Molecular Biomarkers That Link Ischemic Stroke and Moyamoya Disease with Glioblastoma.Pharmaceutics · 2022Article
- Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib.World journal of hepatology · 2022Article
- Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.La Radiologia medica · 2021Article
- Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.Molecular oncology · 2020Article
- Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.Journal of cellular and molecular medicine · 2019Review
- High glucose promotes breast cancer proliferation and metastasis by impairing angiotensinogen expression.Bioscience reports · 2019Article
- EXPRESSION OF THE RENIN-ANGIOTENSIN SYSTEM COMPONENTS IN ONCOLOGIC DISEASES.Acta clinica Croatica · 2019Review
- Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.Journal of neuro-oncology · 2018Article
- Renin angiotensin system and its role in biomarkers and treatment in gliomas.Journal of neuro-oncology · 2018Review
- Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.Journal of neuro-oncology · 2018Article
- Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.PloS one · 2018Article
- Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.BMC cancer · 2017Article
- Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.Molecular oncology · 2016Article
- Hallmarks of glioblastoma: a systematic review.ESMO open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients.
methodsThe study included a total of 82 recurrent glioblastoma patients treated with bevacizumab combination therapy whom were both response and biomarker evaluable. Gene expression of tumor tissue was analyzed by using a customized NanoString platform covering 800 genes. Candidate gene predictors associated with response were analyzed by multivariate logistic and Cox regression analysis.
resultsTwo genes were independently associated with response: Low expression of angiotensinogen (2-fold decrease in AGT; OR = 2.44; 95% CI: 1.45-4.17; P = 0.0009) and high expression of a HLA class II gene (2-fold increase in HLA-DQA1; OR = 1.22; 95% CI: 1.01-1.47; P = 0.04). These two genes were included in a model that is able predict response to bevacizumab combination therapy in clinical practice. When stratified for a validated prognostic index, the predictive model for response was significantly associated with improved overall survival.
conclusionTwo genes (low angiotensinogen and high HLA-class II expression) were predictive for bevacizumab response and were included in a predictive model for response. This model can be used in clinical practice to identify patients who will benefit from bevacizumab combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.